Shares of Pediatrix Medical Group (MD) plummeted 5.25% in Friday's intraday trading session, underperforming the broader market.
The decline in Pediatrix Medical's stock price appears to be driven by multiple analysts lowering their price targets for the company. Truist Securities adjusted its price target for MD from $15 to $18, maintaining a Hold rating. Similarly, Deutsche Bank lowered its target price from $15 to $17 while keeping a Hold rating.
Despite the downward revisions, analysts polled by FactSet still maintain an average overweight rating on Pediatrix Medical with a mean price target of $17.93, indicating potential for upside from the current stock levels.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.